While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...
A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...
News Nation/World FDA’s plan to boost biosimilar drugs could stall at the patent office Nov. 28, 2025 Updated Sat., Nov. 29, 2025 at 9:37 p.m. Food and Drug Administration (FDA) Commissioner Dr. Marty ...
While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results